Regulonix is an early-stage biotechnology company developing non-opioid drugs for chronic pain. By indirectly targeting the sodium channel NaV1.7 – a well-established and genetically validated pain target – and focusing on the signaling pathways that control this channel’s activity, the Regulonix team has isolated compounds demonstrated in animal models to be non-addictive and more effective than morphine. 

Biotechnology

Regulonix Holding

Regulonix Holding's headquarters in Tucson, AZ, United States

This department provides expert guidance and strategic counsel to support organizational decision-making.

Advisory Services

Regulonix Holding's Leadership Team includes Rajesh Khanna.

��

People (4)

Jobs (0)

Other teams

Leadership Team

��������

People (4)

Jobs (0)

Other teams

Leadership Team

��